Search Results - "Monkhorst K"

Local Ischaemia Does Not Influence Anastomotic Healing: An Experimental Study.

Authors: Daams, F. Monkhorst, K. van den Broek, J. et al.

Source: European Surgical Research. May2013, Vol. 50 Issue 1, p24-31. 8p. 3 Diagrams, 2 Graphs.

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.

Authors: Theelen, W. S. M. E. Krijgsman, O. Monkhorst, K. et al.

Source: Journal of Translational Medicine. 7/3/2020, Vol. 18 Issue 1, p1-12. 12p.

1189O Validation of whole genome sequencing in routine clinical practice.

Authors: Monkhorst, K. Samsom, K. Schipper, L. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS784-S784. 1p.

Optimising primary molecular profiling in non-small cell lung cancer.

Authors: Schouten, R. D. Schouten, I. Schuurbiers, M. M. F. et al.

Source: PLoS ONE. 7/31/2024, Vol. 19 Issue 7, p1-15. 15p.

ESMO Recommendations on clinical reporting of genomic test results for solid cancers.

Authors: van de Haar, J. Roepman, P. Andre, F. et al.

Source: Annals of Oncology. Nov2024, Vol. 35 Issue 11, p954-967. 14p.

Identification of epithelialization in high transsphincteric fistulas.

Authors: Mitalas, L. Onkelen, R. Monkhorst, K. et al.

Source: Techniques in Coloproctology. Apr2012, Vol. 16 Issue 2, p113-117. 5p.

680P Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluid.

Authors: van Linder, B.M.H. Brandsma, D. Verhoeven, E. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS490-S491. 2p.

The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.

Authors: Joosten, P.J.M. de Langen, A.J. van der Noort, V. et al.

Source: Lung Cancer (01695002). Nov2021, Vol. 161, p141-151. 11p.

1262P Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance.

Authors: van der Wel, T. Jebbink, M. Badrising, S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS808-S809. 2p.

1226P Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factors.

Authors: van den Heuvel, M. Smith, C.G. Schuurbiers, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS787-S788. 2p.

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.

Authors: van Veggel, B. Madeira R Santos, J.F. Vilacha Hashemi, S.M.S. et al.

Source: Lung Cancer (01695002). Mar2020, Vol. 141, p9-13. 5p.

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

Authors: Thunnissen, E. Lissenberg-Witte, B.I. van den Heuvel, M.M. et al.

Source: Lung Cancer (01695002). Dec2019, Vol. 138, p13-18. 6p.

Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.

Authors: Vries, R de Muller, M Noort, V van der et al.

Source: Annals of Oncology. Oct2019, Vol. 30 Issue 10, p1660-1666. 7p. 1 Chart, 2 Graphs.

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.

Authors: van der Wel, J.W.T. Jebbink, M. van den Broek, D. et al.

Source: Lung Cancer (01695002). Dec2024, Vol. 198, pN.PAG-N.PAG. 1p.

Biologic meshes are not superior to synthetic meshes in ventral hernia repair: an experimental study with long-term follow-up evaluation.

Authors: Ditzel, M. Deerenberg, E. Grotenhuis, N. et al.

Source: Surgical Endoscopy & Other Interventional Techniques. Oct2013, Vol. 27 Issue 10, p3654-3662. 9p. 3 Color Photographs, 2 Charts, 3 Graphs.

1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands.

Authors: van Waalwijk van Doorn-Khosrovani, S. Reparon, C. Koole, S. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS938-S938. 1p.

1249P Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data.

Authors: van Putten, J. Koster, R. Snaebjornsson, P. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS727-S727. 1p.

1133P Whole genome sequencing can classify diagnostically challenging tumors.

Authors: Schipper, L.J. Snaebjornsson, P. Samsom, K.G. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS924-S925. 2p.

1673P Exploring different strategies to incorporate germline analysis in tumor whole genome sequencing.

Authors: Koster, R. Schipper, L. van Beek, D. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1308-S1308. 1p.

1075P Tobacco smoking related mutational signatures (MS) in classifying smoking and non-smoking associated metastatic non-small cell lung cancer (mNSCLC).

Authors: Ernst, S.M. Mankor, J. van Riet, J. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1045-S1045. 1p.